PTC Therapeutics, Inc. (PTCT) Stock Price & Analysis
PTC Therapeutics, Inc. (PTCT) closed at USD 63.04 on Thursday, October 22, 2026, up 0.67% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 62.62; the Oct 22, 2026 session ranged USD 62.24–63.49 on volume of 675,442 shares. Market capitalization is $5.26B, with a 52-week range of USD 58.8–90.87 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PTCT.md
Key facts (PTCT)
- Last four reported quarters (through Jun 30, 2026): revenue $1.01B, net income -$38.4M (-3.8% margin), free cash flow -$39.8M (SEC filings).
- 1 of 80 tracked superinvestors hold PTCT (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 28 Form 4 filings, $25.5M; 0 not under a Rule 10b5-1 plan ($0K); 1 by opportunistic insiders (0 outside 10b5-1 plans), 18 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (16 analysts), mean target USD 97.81 (range 62–137).
- Total return with dividends: 1Y -5.6% vs S&P 500 +14.9%; 5Y +75.2% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 0.3, revenue estimate $305M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PTCT)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $539M | $699M | $938M | $807M | $1.73B | $1.01B |
| Operating income | -$374M | -$447M | -$440M | -$303M | $867M | $126M |
| Net income | -$524M | -$559M | -$627M | -$363M | $683M | -$38.4M |
| EPS (diluted) | -$7.43 | -$7.79 | -$8.37 | -$4.73 | $7.78 | — |
| Free cash flow | -$280M | -$389M | -$187M | -$114M | $702M | -$39.8M |
| Operating margin | -69.5% | -64.0% | -46.9% | -37.5% | 50.1% | 12.5% |
| Net margin | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% | -3.8% |
| Revenue growth | +41.4% | +29.7% | +34.2% | -14.0% | +114.5% | — |
| Cash + short-term investments | $773M | $411M | $877M | $1.14B | $1.95B | — |
| Total debt | $431M | $572M | $284M | $285M | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PTCT)
P/S 5.2x · EV/EBITDA 20.0x · EV/Sales 3.6x · FCF yield -0.76% · Earnings yield -0.73% · Net cash $1.64B · EV $3.62B
P/E at fiscal year-ends: Dec 2025 9.8x.
Superinvestors (SEC 13F-HR, Q2 2026) (PTCT)
1 of 80 tracked investors hold PTCT. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 0.02% | $2.0M | New position |
Insider sales (SEC Form 4, open-market, last ~7 months) (PTCT)
28 of 28 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Schmertzler Michael | Director | 2,500 | $149K | 0.2% | Yes | Too little history (no open-market trades in 2025) |
| 2026-10-09 | Boulding Mark Elliott | EXEC. VP AND CLO | 192 | $12K | 0.2% | Yes (adopted September 10, 2025) | Routine (sold in Jan each year 2023–2025; this trade is outside those months) |
| 2026-10-07 | Schmertzler Michael | Director | 2,500 | $158K | 0.2% | Yes | Too little history (no open-market trades in 2025) |
| 2026-10-05…2026-10-06 | Boulding Mark Elliott | EXEC. VP AND CLO | 2,073 | $133K | 1.9% | Yes (adopted September 10, 2025) | Routine (sold in Jan each year 2023–2025; this trade is outside those months) |
| 2026-09-30 | Steele Glenn Jr Md Phd | Director | 12,000 | $782K | 34.8% | Yes (adopted March 9, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-09-16…2026-09-17 | Schmertzler Michael | Director | 20,000 | $1.3M | 1.4% | Yes | Too little history (no open-market trades in 2025) |
| 2026-09-09…2026-09-10 | Schmertzler Michael | Director | 20,000 | $1.4M | 1.5% | Yes | Too little history (no open-market trades in 2025) |
| 2026-08-26…2026-08-27 | Schmertzler Michael | Director | 25,000 | $1.8M | 1.6% | Yes | Too little history (no open-market trades in 2025) |
| 2026-08-19…2026-08-20 | Schmertzler Michael | Director | 25,000 | $1.8M | 1.6% | Yes | Too little history (no open-market trades in 2025) |
| 2026-08-17 | Boulding Mark Elliott | EXEC. VP AND CLO | 2,813 | $204K | 2.6% | Yes (adopted September 10, 2025) | Routine (sold in Jan each year 2023–2025; this trade is outside those months) |
| 2026-08-04 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | 10,292 | $706K | 2.6% | Yes | Routine (sold in Jan & Apr each year 2023–2025; this trade is outside those months) |
| 2026-07-14 | Gravier Pierre | CHIEF FINANCIAL OFFICER | 3,494 | $281K | 4% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-07-09 | Smith Mary L. | Director | 15,834 | $1.4M | 42.1% | Yes (adopted November 11, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-07-09 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 2,464 | $222K | 3.8% | Yes (adopted November 11, 2025) | Routine (sold in Jan each year 2023–2025; this trade is outside those months) |
| 2026-07-06…2026-07-07 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 46,774 | $4.1M | 42.5% | Yes (adopted November 11, 2025) | Routine (sold in Jan each year 2023–2025; this trade is outside those months) |
| 2026-07-06 | Boulding Mark Elliott | EXEC. VP AND CLO | 5,079 | $432K | 4.6% | Yes (adopted September 10, 2025) | Routine (sold in Jan each year 2023–2025; this trade is outside those months) |
| 2026-06-26 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 8,130 | $693K | 11.5% | Yes (adopted November 11, 2025) | Routine (sold in Jan each year 2023–2025; this trade is outside those months) |
| 2026-06-24…2026-06-25 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 26,283 | $2.3M | 30.4% | Yes (adopted November 11, 2025) | Routine (sold in Jan each year 2023–2025; this trade is outside those months) |
| 2026-06-22 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 23,749 | $1.9M | 27.4% | Yes (adopted November 11, 2025) | Routine (sold in Jan each year 2023–2025; this trade is outside those months) |
| 2026-06-17 | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | 19,686 | $1.5M | 21.9% | Yes (adopted March 17, 2026) | Routine (sold in Jan each year 2023–2025; this trade is outside those months) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (PTCT)
Consensus Buy (mean 2.00 on a 1–5 scale), 16 analysts; mean target USD 97.81 (low 62, high 137).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | RBC Capital | Target lowered | Sector Perform | $85 → $75 |
| 2026-09-22 | Cantor Fitzgerald | Target raised | Overweight | $130 → $137 |
| 2026-08-14 | Barclays | Target raised | Overweight | $120 → $122 |
| 2026-08-13 | Wells Fargo | Target raised | Overweight | $106 → $109 |
| 2026-07-31 | Morgan Stanley | Target raised | Overweight | $93 → $104 |
| 2026-07-31 | Wells Fargo | Target raised | Overweight | $93 → $106 |
| 2026-07-20 | Wells Fargo | Target lowered | Overweight | $95 → $93 |
| 2026-07-16 | Cantor Fitzgerald | Target raised | Overweight | $124 → $130 |
| 2026-07-07 | RBC Capital | Target raised | Sector Perform | $82 → $85 |
Total return (dividends reinvested) (PTCT)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -5.6% | +75.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -5.7% | +11.8% |
| Volatility (annualized) | 40.5% | 55.9% |
| Max drawdown | -33.9% (Jul 2026→Oct 2026) | -68.3% (May 2023→Oct 2023) |
PTCT revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $238.8M | 66.2% | +101.8% |
| — Sephience (part of Product) | $151.3M | 42.0% | — |
| — Translarna (part of Product) | $42.2M | 11.7% | -29.0% |
| — Emflaza (part of Product) | $24.6M | 6.8% | -32.2% |
| — Upstaza & Kebilidi (part of Product) | $11.2M | 3.1% | -6.1% |
| — Other Products (part of Product) | $9.5M | 2.6% | -10.6% |
| Royalty | $71.1M | 19.7% | +23.4% |
| Collaboration & License Revenue | $50.6M | 14.0% | +1620.3% |
| Total revenue | $360.5M | 100% | — |
PTCT revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $152.2M | 42.2% | +318.6% |
| All Other Countries Other Than Russia Brazil & United States | $52.8M | 14.7% | +130.7% |
| Brazil | $25.6M | 7.1% | +41.1% |
| Russia | $8.2M | 2.3% | -80.0% |
| Total revenue | $360.5M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
PTCT suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Akcea Therapeutics | “In addition, Akcea has granted to us a non-exclusive right and license, with the right to grant certain sublicenses, under Akcea's core intellectual property and manufacturing intellectual property to develop, manufacture and commercialize the Products in the PTC Territory and to manufacture the Products worldwide in accordance with a supply agreement with Akcea.” |
| Supplier | Faes Farma | “Under an Exclusive License and Supply Agreement, or the Faes Agreement, with Faes Farma, S.A., or Faes, we are required to pay royalties as a percentage of or as a fixed payment with respect to net product sales by us allocable to the Emflaza oral suspension product.” |
| Partner | Novartis Pharmaceuticals | “In November 2024, we entered into a License and Collaboration Agreement with Novartis Pharmaceuticals Corporation, or Novartis, relating to our votoplam program, or the Novartis Agreement, which included related molecules.” |
| Partner | Royalty Pharma plc (RPRX) | “Pursuant to Amendment No. 2, we sold to Royalty Pharma our retained right to receive sales-based royalty payments, or the Royalty, on worldwide net sales of Evrysdi and any other product developed pursuant to the SMA License Agreement under the SMA Program in exchange for $240.0 million in upfront cash consideration, and three potential additional cash purchase price payments of $20.0 million each conditioned upon…” |
| Partner | Shiratori Pharmaceutical | “We currently have ongoing collaborations with Roche and the SMA Foundation for SMA, a license agreement with National Taiwan University, or NTU, for Upstaza, a collaboration and license agreement with Akcea for Tegsedi and Waylivra, a license agreement with Shiratori Pharmaceutical Co., Ltd., or Shiratori, relating to the manufacturing processes and technology for sepiapterin, and a license and collaboration agree…” |
| Partner | IONIS PHARMACEUTICALS INC (IONS) | “PTC Therapeutics International Limited, our subsidiary, entered into a Collaboration and License Agreement, or the Tegsedi-Waylivra Agreement, dated August 1, 2018 by and between us and Akcea, a subsidiary of Ionis Pharmaceuticals, Inc., for the commercialization by us of Tegsedi, Waylivra and products containing those compounds, which we refer to collectively as the Products, in countries in Latin America and the…” |
| Partner | Agilis Biotherapeutics | “Pursuant to the license and technology transfer agreement, originally entered into between Agilis Biotherapeutics, Inc., or Agilis, NTU and Professor Wuh-Liang (Paul) Hwu, in December 2015, or the NTU Licensing Agreement, NTU granted to us an exclusive, perpetual license, with the right to grant sublicenses through all tiers, to research and use the intellectual property, data, chemistry, manufacturing and control…” |
| Partner | Fitzgerald and RBC Capital Markets | “Sales of substantial amounts of shares of our common stock or other securities by our stockholders or by us, including sales made under our At the Market Offering Sales Agreement with Cantor Fitzgerald and RBC Capital Markets, LLC, pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $125 million from time to time, through the Sales Agent by any method that…” |
Quoted from the company's 10-K filed Feb 19, 2026.
Companies that name PTCT in their SEC reports
| Relationship to PTCT | Company | Filing | Sentence |
|---|---|---|---|
| partner | Lexeo Therapeutics, Inc. (LXEO) | 10-K Mar 30, 2026 | “With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…” |
| partner | PRECIGEN, INC. (PGEN) | 10-K Mar 25, 2026 | “In September 2025, the Company and PTC Therapeutics mutually agreed to terminate their existing exclusive channel collaboration ("ECC") agreement.” |
PTCT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.30 | $0.54 | -44.1% | $304.6M | 3 |
| Next quarter (ends Dec 2026) | $0.18 | $0.53 | -66.9% | $319.0M | 3 |
| Current fiscal year (ends Dec 2026) | $1.52 | $1.49 | +1.8% | $1.26B | 3 |
| Next fiscal year (ends Dec 2027) | $2.37 | $3.09 | -23.2% | $1.38B | 3 |
PTCT options: expected move
Options price a move of about ±13.6% (±$8.55) by Nov 20, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±6.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 58.6% | ±13.6% |
| Dec 18, 2026 | 56 | 56.2% | ±18.1% |
| Jan 15, 2027 | 84 | 59.5% | ±23.2% |
| Mar 19, 2027 | 147 | 57.5% | ±29.4% |
| Jun 17, 2027 | 237 | 54.5% | ±35.2% |
30-day implied volatility 57.1% vs 38.5% realized over the last 30 trading days. Put/call ratio (volume) 0.05. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:21 UTC)
| Price | USD 63.04 |
|---|---|
| Change | ▲ 0.67% (up) |
| Previous Close | USD 62.62 |
| Open | USD 62.62 |
| Day Range | USD 62.24 – 63.49 |
| 52-Week Range | USD 58.8 – 90.87 |
| Volume | 675,442 shares |
| Market Cap | $5.26B |
| Exchange | NMS |
Technical Analysis (PTCT)
Nexqual's technical model rates PTCT "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:21 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.74 (neutral) |
| vs SMA50 | Below (USD 66.61) |
| MACD | -1.33 (negative) |
Analyst Ratings (PTCT)
Wall Street analysts rate PTCT "Buy" based on 16 analysts, with a mean price target of USD 97.81 (range USD 62–137), per Nexqual as of October 23, 2026 at 09:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 97.81 |
| High Target | USD 137 |
| Low Target | USD 62 |
| Buy / Hold / Sell | 13 / 2 / 1 |
Earnings (PTCT)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 0.3 |
| Revenue Estimate | $304.57M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.92 vs est 0.34 ▲ beat |
| 2026-03-31 | USD -0.03 vs est -0.44 ▲ beat |
| 2025-12-31 | USD -1.8 vs est -0.41 ▼ miss |
| 2025-09-30 | USD 0.19 vs est -1.11 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financials & Fundamentals (PTCT)
| Total Revenue | $1.01B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +101.50% |
| Gross Margin | +49.96% |
| Operating Margin | +41.32% |
| Profit Margin | -3.81% |
| Current Ratio | 3.39 |
| Total Cash | $2.23B |
| Total Debt | $3.02B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$39.78M (-3.9% of revenue) |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financial Health Score (PTCT)
Nexqual rates PTC Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:21 UTC.
| Growth | Strong — Revenue +115% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 50%, operating 41% (last 12 months) |
| Balance Sheet | Mixed — $2.23B cash and investments vs $591M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$40M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Mixed — No data |
Ownership (PTCT)
| Insider Ownership | +7.31% |
|---|---|
| Institutional Ownership | +122.78% |
| Shares Outstanding | 83.46M |
| Float | 73.69M |
| Short % of Float | +14.89% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Leadership (PTCT)
PTC Therapeutics, Inc. is led by Matthew B. Klein F.A.C.S., M.D., M.S., CEO & Director, per Nexqual as of October 23, 2026 at 09:21 UTC.
| CEO & Director | Matthew B. Klein F.A.C.S., M.D., M.S. |
|---|---|
| Co-Founder & Independent Director | Allan Steven Jacobson |
| Chief Financial Officer | Pierre Gravier M.S. |
Major Backers & Investors (PTCT)
Notable institutional backers of PTC Therapeutics, Inc. include RTW Investments LP, Jupiter Topco LLC, Wellington Management, according to Nexqual as of October 23, 2026 at 09:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 9.28% |
| Jupiter Topco LLC | 8.67% |
| Wellington Management | 4.95% |
| Toronto Dominion Bank | 2.6% |
| Westfield Capital Management Co LP | 2.34% |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 16.73% |
| Vanguard Group | 10.38% |
| State Street | 5.51% |
| Geode Capital | 2.64% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
From PTC Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Careful control and manipulation of these processes allow us to address a wide range of deficiencies.
Partnerships
- In November 2024, we entered into a License and Collaboration Agreement with Novartis Pharmaceuticals Corporation, or Novartis, relating to our votoplam program, or the Novartis Agreement, which included related molecules.
- We currently have ongoing collaborations with Roche and the SMA Foundation for SMA, a license agreement with National Taiwan University, or NTU, for Upstaza, a collaboration and license agreement with Akcea for Tegsedi and Waylivra, a license agreement with Shiratori Pharmaceutical Co., Ltd., or Shiratori, relating to the manufacturing processes and technology for sepiapterin, and a license and collaboration agreement with Novartis for our votoplam HD program.
Legal & Regulatory Risks (Item 1A, quoted)
- We may not be able to obtain orphan drug exclusivity for our products or product candidates in either the United States or the EU.
- Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs.
- The respective orphan designation and exclusivity frameworks in the United States and in the EU are subject to change, and any such changes may affect our ability to obtain, or the impact of obtaining, United States or EU orphan designations in the future.
- We may face competition from biosimilar, generic, and similar products approved through abbreviated pathways, as well as products approved pursuant to full applications.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BLTE | Belite Bio, Inc | USD 150.27 | ▼ 1.9% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| TGTX | TG Therapeutics, Inc. | USD 53.16 | ▼ 0.08% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt